» Articles » PMID: 35225118

Collagen Misfolding Mutations: the Contribution of the Unfolded Protein Response to the Molecular Pathology

Overview
Publisher Informa Healthcare
Date 2022 Feb 28
PMID 35225118
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in collagen genes cause a broad range of connective tissue pathologies. Structural mutations that impact procollagen assembly or triple helix formation and stability are a common and important mutation class. How misfolded procollagens engage with the cellular proteostasis machinery and whether they can elicit a cytotoxic unfolded protein response (UPR) is a topic of considerable research interest. Such interest is well justified since modulating the UPR could offer a new approach to treat collagenopathies for which there are no current disease mechanism-targeting therapies. This review scrutinizes the evidence underpinning the view that endoplasmic reticulum stress and chronic UPR activation contributes significantly to the pathophysiology of the collagenopathies. While there is strong evidence that the UPR contributes to the pathology for collagen X misfolding mutations, the evidence that misfolding mutations in other collagen types induce a canonical, cytotoxic UPR is incomplete. To gain a more comprehensive understanding about how the UPR amplifies to pathology, and thus what types of manipulations of the UPR might have therapeutic relevance, much more information is needed about how specific misfolding mutation types engage differentially with the UPR and downstream signaling responses. Most importantly, since the capacity of the proteostasis machinery to respond to collagen misfolding is likely to vary between cell types, reflecting their functional roles in collagen and extracellular matrix biosynthesis, detailed studies on the UPR should focus as much as possible on the actual target cells involved in the collagen pathologies.

Citing Articles

Mutation Causing Pediatric Macular Chorioretinal Atrophy Associated With Stickler Syndrome.

Shah S, Lopez-Font F, Fan J, Cruz N, Staropoli P, Negron C J Vitreoretin Dis. 2025; :24741264241309682.

PMID: 39744646 PMC: 11686495. DOI: 10.1177/24741264241309682.


Human cartilage model of the precocious osteoarthritis-inducing p.Arg719Cys reveals pathology-driving matrix defects and a failure of the ER proteostasis network to recognize the defective procollagen-II.

Yammine K, Abularach S, Xiong M, Kim S, Bikovtseva A, Butty V bioRxiv. 2024; .

PMID: 39574595 PMC: 11580999. DOI: 10.1101/2024.11.07.622468.


Comparative Transcriptome Analysis of Bovine, Porcine, and Sheep Muscle Using Interpretable Machine Learning Models.

Guo Y, Li S, Na R, Guo L, Huo C, Zhu L Animals (Basel). 2024; 14(20).

PMID: 39457877 PMC: 11506101. DOI: 10.3390/ani14202947.


Bone Quality and Mineralization and Effects of Treatment in Osteogenesis Imperfecta.

Misof B, Fratzl-Zelman N Calcif Tissue Int. 2024; 115(6):777-804.

PMID: 39231826 DOI: 10.1007/s00223-024-01263-8.


Mechanisms of assembly and remodelling of the extracellular matrix.

Naba A Nat Rev Mol Cell Biol. 2024; 25(11):865-885.

PMID: 39223427 DOI: 10.1038/s41580-024-00767-3.


References
1.
Lamande S, Chessler S, Golub S, Byers P, Chan D, Cole W . Endoplasmic reticulum-mediated quality control of type I collagen production by cells from osteogenesis imperfecta patients with mutations in the pro alpha 1 (I) chain carboxyl-terminal propeptide which impair subunit assembly. J Biol Chem. 1995; 270(15):8642-9. DOI: 10.1074/jbc.270.15.8642. View

2.
Mirigian L, Makareeva E, Mertz E, Omari S, Roberts-Pilgrim A, Oestreich A . Osteoblast Malfunction Caused by Cell Stress Response to Procollagen Misfolding in α2(I)-G610C Mouse Model of Osteogenesis Imperfecta. J Bone Miner Res. 2016; 31(8):1608-1616. PMC: 5061462. DOI: 10.1002/jbmr.2824. View

3.
Garibaldi N, Contento B, Babini G, Morini J, Siciliani S, Biggiogera M . Targeting cellular stress in vitro improves osteoblast homeostasis, matrix collagen content and mineralization in two murine models of osteogenesis imperfecta. Matrix Biol. 2021; 98:1-20. PMC: 11162743. DOI: 10.1016/j.matbio.2021.03.001. View

4.
Chan D, Cole W, Chow C, Mundlos S, Bateman J . A COL2A1 mutation in achondrogenesis type II results in the replacement of type II collagen by type I and III collagens in cartilage. J Biol Chem. 1995; 270(4):1747-53. View

5.
Chiarelli N, Carini G, Zoppi N, Ritelli M, Colombi M . Transcriptome analysis of skin fibroblasts with dominant negative COL3A1 mutations provides molecular insights into the etiopathology of vascular Ehlers-Danlos syndrome. PLoS One. 2018; 13(1):e0191220. PMC: 5773204. DOI: 10.1371/journal.pone.0191220. View